Annexon, Inc.

NASDAQ:ANNX

Biotechnology

Healthcare
$3.52 -0.71%

-$0.04 today

Market cap
$576.73M
Beta
1.18
P/E (TTM)
-4.8
EPS (TTM)
-$1.01
52W Low $1.85High $7.18

Volume 2.98M

Average 2.56M

ANNX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Annexon, Inc.NASDAQ: ANNX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $35.79M fell 25.7% year over year, behind the +17.5% change in trailing-twelve-month research & development. Sequentially, it fell 16.1% from the prior quarter. Over 3 fiscal years it compounded at +18.0% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -25.7% toward the trailing-twelve-month pace of +17.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$35.79M-16.1% QoQ
Last fiscal yearDec 2025
$184.7M+54.6% YoY
LTMMar 2026
$172.31M+17.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.7%——
1 year+54.6%——
3-year CAGR+18.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
184.7M USD
Year-over-year change
+54.6%
4-year CAGR
+16.6%

Research & Development vs competitors

How ANNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +17.5% is the 3rd highest of 11, against a peer median of -13.1%.
  • Over three fiscal years its annual growth of +18.0% compares with a peer median of +3.0%.
ANNX Competitors
Research & Development for ANNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMVTImmunovant, Inc.LTM Sep 2026$468.85M USD+16.2%+41.8%6608.2%
ALMSAlumis Inc. Common StockLTM Jun 2026$346.63M USD-8.7%+56.3%4685.4%
XNCRXencor, Inc.LTM Jun 2026$255.77M USD+11.4%+6.3%243.6%
ABVXAbivax S.A.FY2025€177.76M EUR+21.3%+54.4%—
ANNXAnnexon, Inc.LTM Mar 2026$172.31M USD+17.5%+18.0%—
ANABAnaptysBio, Inc.LTM Mar 2026$128.65M USD-23.4%+15.3%55.4%
PRTAProthena Corporation plcLTM Mar 2026$96.67M USD-53.8%-0.2%166.8%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$56.72M USD+60.6%-12.2%677.9%
ACIUAC Immune S.A.LTM Mar 2026CHF 52.18M CHF-17.6%-2.2%1409.6%
IFRXInflaRx N.V.LTM Mar 2026€22.87M EUR-34.8%-11.8%77989.1%
QTTBQ32 Bio Inc.LTM Mar 2026$15.25M USD-66.4%-18.8%28.4%
Peer median (excluding ANNX) —-13.1%+3.0%677.9%

Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0003.45M3.69M
Gross Profit000(3.45M)(3.69M)
Gross Margin—————
Research & Development100.07M112.5M113.76M119.45M184.7M
Selling, General & Admin30.65M30.95M28.02M34.63M31.71M
Operating Expenses130.71M145.6M143.72M150.62M212.72M
Depreciation & Amortization2.14M2.15M2.15M3.45M2.65M
EBITDA(128.18M)(139.8M)(132.09M)(134.75M)(204.04M)
EBITDA Margin—————
Operating Income(130.71M)(145.6M)(143.72M)(154.07M)(216.41M)
Operating Margin—————
Interest Income390K3.65M9.49M15.87M9.72M
Interest Expense00000
Other Income / Expenses390K3.65M9.49M15.87M9.72M
Income Before Tax(130.32M)(141.95M)(134.24M)(138.2M)(206.69M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(130.32M)(141.95M)(134.24M)(138.2M)(206.69M)
Net Margin—————
EPS (Basic)(3.34)(2.60)(1.77)(1.01)(1.34)
EPS (Diluted)(3.34)(2.60)(1.77)(1.01)(1.34)
Weighted Avg Shares38.32M54.67M75.67M137.4M155.11M
Weighted Avg Shares (Diluted)38.32M54.67M75.67M137.4M155.11M

Annexon, Inc.

NASDAQ:ANNX

Intrinsic Alpha fair value

Locked

Current Price

$3.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.